Jayakumar Sreenivasan

Jayakumar Sreenivasan

Auto-generated profile, based on publicly available information

Jayakumar Sreenivasan

Section of Cardiovascular Medicine Yale University School of Medicine New Haven CT USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
Muhammad Shahzeb KhanMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
NLNoman Lateef
Noman Lateef
MAMarwan S. Abougergi
Marwan S. Abougergi
SGStephen J. Greene
Stephen J. Greene
JBJaved Butler
Javed Butler
Background: The impact of hospital readmission reduction program (HRRP) on heart failure (HF) outcomes has been debated. Limited data exist regarding trends of HF readmission rates beyond 30 days from all-payer sources. The aim of this study was to investigate temporal trends of 30- and 90-day HF readmissions rates from 2010 to 2017 in patients from all-payer sources. Methods: The National Readmission Database was utilized to identify HF hospitalizations between 2010 and 2017. In the primary analysis, a linear trend in 30-day and 90-day readmissions from 2010 to 2017 was assessed. While in the secondary analysis, a change in aggregated 30- and 90-day all-cause and HF-specific readmissions pre-HRRP penalty phase (2010–2012) and post-HRRP penalties (2013–2017) was compared. Subgroup analyses were performed based on (1) Medicare versus non-Medicare insurance, (2) low versus high HF volume, and (3) HF with reduced versus preserved ejection fraction (heart failure with reduced ejection fraction and heart failure with preserved ejection fraction). Multiple logistic and adjusted linear regression analyses were performed for annual trends. Results: A total of 6 669 313 index HF hospitalizations for 30-day, and 5 077 949 index HF hospitalizations for 90-day readmission, were included. Of these, 1 213 402 (18.2%) encounters had a readmission within 30 days, and 1 585 445 (31.2%) encounters had a readmission within 90 days. Between 2010 and 2017, both 30 and 90 days adjusted HF-specific and all-cause readmissions increased (8.1% to 8.7%, P trend 0.04, and 18.3% to 19.9%, P trend <0.001 for 30-day and 14.8% to 16.0% and 30.9% to 34.6% for 90-day, P trend <0.001 for both, respectively). Readmission rates were higher during the post-HRRP penalty period compared with pre-HRRP penalty phase (all-cause readmission 30 days: 18.6% versus 17.5%, P <0.001, all-cause readmission 90 days: 32.0% versus 29.9%, P <0.001) across all subgroups except among the low-volume hospitals. Conclusions: The rates of adjusted HF-specific and all-cause 30- and 90-day readmissions have increased from 2010 to 2017. Readmissions rates were higher during the HRRP phase across all subgroups except the low-volume hospitals.

26 January 2018 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
MUMuhammad Shariq Usman
Muhammad Shariq Usman
TSTariq Jamal Siddiqi
Tariq Jamal Siddiqi
MMMuhammad Mustafa Memon
Muhammad Mustafa Memon
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
WRWasiq Faraz Rawasia
Wasiq Faraz Rawasia
YGYasmeen Golzar
Yasmeen Golzar
Background: The risks and benefits of sodium-glucose co-transporter 2 (SGLT2) inhibitors on cardiovascular outcomes have not been well established. We pooled evidence from all available clinical trials to assess the cardiovascular effects of this drug. Design: A systematic review and meta-analysis of randomised controlled trials. Methods: We queried electronic databases (MEDLINE, Scopus, CENTRAL and clinicaltrials.gov) from their inception to July 2017 for published and unpublished placebo controlled trials of SGLT2 inhibitors. Only studies with a follow-up period of at least 24 weeks and reporting at least one cardiovascular outcome were included. Results from trials were presented as odds ratios (ORs) with 95% confidence intervals (CIs) and were pooled using a random-effects model. Results: Thirty-five eligible studies (canagliflozin, nine; empagliflozin, eight; dapagliflozin, 18), consisting of 34,987 patients with type 2 diabetes mellitus were included. Pooled results show that SGLT2 inhibitors, when compared to placebo, significantly reduce all-cause mortality (OR 0.79, 95% CI 0.70–0.89; P < 0.001), major adverse cardiac events (OR 0.8, 95% CI 0.76–0.92; P < 0.001), non-fatal myocardial infarction (OR 0.85, 95% CI 0.73–0.98; P = 0.03) and heart failure/hospitalisation for heart failure (OR 0.67, 95% CI 0.59–0.76; P < 0.001) in patients with type 2 diabetes mellitus. No significant difference was noted in the occurrence of stroke (OR 1.02, 95% CI 0.85–1.21; P = 0.87), atrial fibrillation (OR 0.61, 95% CI 0.31–1.19; P = 0.15) or unstable angina (OR 0.95, 95% CI 0.73–1.25; P = 0.73). In addition, there was no heterogeneity between different drugs in the SGLT2 inhibitor class for all of the clinical outcomes studied ( I2 = 0). Conclusions: SGLT2 inhibitors significantly reduce the incidence of mortality, major adverse cardiac events, non-fatal myocardial infarction and heart failure in patients with type 2 diabetes mellitus. Subtypes of SGLT2 inhibitors appear to have similar cardiovascular effects.

16 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
RRRohin Reddy
Rohin Reddy
YJYasser Jamil
Yasser Jamil
AMAaqib Malik
Aaqib Malik
DCDaniel Chamie
Daniel Chamie
YAYousif Ahmad
Yousif Ahmad
Background: Despite the initial evidence supporting the utility of intravascular imaging to guide percutaneous coronary intervention (PCI), adoption remains low. Recent new trial data have become available. An updated study‐level meta‐analysis comparing intravascular imaging to angiography to guide PCI was performed. This study aimed to evaluate the clinical outcomes of intravascular imaging–guided PCI compared with angiography‐guided PCI. Methods and Results: A random‐effects meta‐analysis was performed on the basis of the intention‐to‐treat principle. The primary outcomes were major adverse cardiac events, cardiac death, and all‐cause death. Mixed‐effects meta‐regression was performed to investigate the impact of complex PCI on the primary outcomes. A total of 16 trials with 7814 patients were included. The weighted mean follow‐up duration was 28.8 months. Intravascular imaging led to a lower risk of major adverse cardiac events (relative risk [RR], 0.67 [95% CI, 0.55–0.82]; P <0.001), cardiac death (RR, 0.49 [95% CI, 0.34–0.71]; P <0.001), stent thrombosis (RR, 0.63 [95% CI, 0.40–0.99]; P =0.046), target‐lesion revascularization (RR, 0.67 [95% CI, 0.49–0.91]; P =0.01), and target‐vessel revascularization (RR, 0.60 [95% CI, 0.45–0.80]; P <0.001). In complex lesion subsets, the point estimate for imaging‐guided PCI compared with angiography‐guided PCI for all‐cause death was a RR of 0.75 (95% CI, 0.55–1.02; P =0.07). Conclusions: In patients undergoing PCI, intravascular imaging is associated with reductions in major adverse cardiac events, cardiac death, stent thrombosis, target‐lesion revascularization, and target‐vessel revascularization. The magnitude of benefit is large and consistent across all included studies. There may also be benefits in all‐cause death, particularly in complex lesion subsets. These results support the use of intravascular imaging as standard of care and updates of clinical guidelines.

1 April 2021 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
PKPankaj Kumar
Pankaj Kumar
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
SKSafi U. Khan
Safi U. Khan
KNKhurram Nasir
Khurram Nasir
HWHaider J. Warraich
Haider J. Warraich

28 July 2020 in ASAIO Journal
Verified
Journal Article
Closed access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
RKRisheek Kaul
Risheek Kaul
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
SRSagar Ranka
Sagar Ranka
RDRyan T. Demmer
Ryan T. Demmer
PCPaolo C. Colombo
Paolo C. Colombo
Left ventricular assist device (LVAD) implantation in patients with advanced heart failure due to hypertrophic or restrictive cardiomyopathy (HCM/RCM) presents technical and physiologic challenges. We conducted a systematic review of observational studies to evaluate the utilization and clinical outcomes associated with LVAD implantation in patients with HCM/RCM and compared these to patients with dilated or ischemic cardiomyopathy (DCM/ICM). We searched MEDLINE, EMBASE, and Scopus from inception through May 2019 and included appropriate studies describing the use of an LVAD in patients with HCM/RCM. We identified six studies with a total of 2,766 patients with HCM/RCM and advanced heart failure, among whom 338 patients (12.2%) underwent LVAD implantation. In patients listed for transplant, the rate of LVAD implantation was significantly lower in patients with HCM/RCM compared to that in patients with DCM/ICM (4.4% vs. 18.2%, p < 0.001). Adverse clinical outcomes were significantly higher in HCM/RCM than in DCM/ICM, including operative/short-term mortality (14.0% vs. 9.0%), right ventricular failure (50.0% vs. 21.0%), infection (15.5% vs. 11.2%), bleeding (40.2% vs. 12.5%), renal failure (15.0% vs. 5.1%), stroke (5.0% vs. 2.4%), and arrhythmias (18.0% vs. 7.7%) (all p values <0.001).

1 September 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JSJayakumar Sreenivasan
Jayakumar Sreenivasan
MZMin Zhuo
Min Zhuo
MKMuhammad Shahzeb Khan
Muhammad Shahzeb Khan
HLHeyi Li
Heyi Li
SFSetri Fugar
Setri Fugar
NYNeha Yadav
Neha Yadav